Clozaril Articles
1992 NET PROFITS SURGE 34% AT SANDOZ
5 April 1993
CLOZAPINE RATIONING
22 March 1993
SANDOZ 1992 SALES SEE 8% INCREASE
1 February 1993
ZENECA'S PROMISING R&D PIPELINE PRESENTED
14 December 1992
EUROPE STOCK COMMENT
7 December 1992
COUNTING THE COST OF SCHIZOPHRENIA
7 December 1992
CLOZARIL CHANGES D2 ANTAGONIST THEORY
3 August 1992
Sandoz schizophrenia therapy
6 July 1992
"STRINGS" WITH US ACCELERATED APPRO
27 April 1992
BROKER UPGRADES SWISS DRUG MAJORS
20 April 1992
FOCUS ON JANSSEN'S RISPERDOL
16 March 1992
ANALYST R&D UPDATE FROM ICI
6 January 1992
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Is the diabetes market facing a blockbuster-free future?
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
